RxDoctor Payments Data

Zachary Fletcher, DO

Internal Medicine · Festus, MONPI 1184184525

Payments from drug & device makers

$2,503in general payments, 2019–2025

Across 130 payments — averaging $19.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$341
  • Lilly USA, LLC$331
  • AbbVie$274
  • Intuitive Surgical$135
  • Novo Nordisk$119
  • GSK$108
  • plus $1K from 29 others

What the payments were for

  • Food & beverage$2,495100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,503 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$41,053
Medicare patients
205
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban67$54,021
OzempicSemaglutide36$48,090
JardianceEmpagliflozin41$46,467
TrulicityDulaglutide19$33,727
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$25,170
MounjaroTirzepatide22$23,068
XareltoRivaroxaban14$15,800
MyrbetriqMirabegron18$11,421
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$10,453
Combivent RespimatIpratropium/Albuterol Sulfate11$5,289
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$3,632
Lubiprostone12$2,601
Atorvastatin Calcium283$2,492
Gabapentin128$1,965
Esomeprazole Magnesium31$1,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$331$56,79541 claims
PfizerEliquis$101$54,02167 claims
Boehringer IngelheimJardiance, Combivent Respimat$31$51,75652 claims
Novo NordiskOzempic$119$48,09036 claims
GSKTrelegy Ellipta$108$25,17039 claims
Johnson & JohnsonXarelto$54$15,80014 claims
Astellas Pharma US IncMyrbetriq$88$11,42118 claims
AstraZenecaBreztri Aerosphere$341$10,45312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Festus

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →